As of Apr 28
| -0.0699 / -6.99%|
The 2 analysts offering 12-month price forecasts for Protalix Biotherapeutics Inc have a median target of 3.40, with a high estimate of 5.00 and a low estimate of 1.80. The median estimate represents a +265.59% increase from the last price of 0.93.
The current consensus among 2 polled investment analysts is to Buy stock in Protalix Biotherapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.